https://www.healthcaretribunefrance.com/article/914318521-cancer-vaccines-market-to-witness-massive-growth-by-2033-neovax-bio-celluvax-inc Healthcare Tribune France en PressRelease 2026-05-22T11:41:51+00:00 Cancer Vaccines Market to Witness Massive Growth by 2033 | NeoVax Bio, CelluVax Inc. https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24864507-cancer-vaccines-market-1024x1024.jpeg https://www.healthcaretribunefrance.com/article/914437169-abivax-presents-first-quarter-2026-financial-results-and-reports-three-year-interim-data-from-study-108-a-phase-2a-2b-open-label-extension-trial-of Healthcare Tribune France en PressRelease 2026-05-22T20:05:00+00:00 Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis https://ml-eu.globenewswire.com/media/5470cd7e-c1fe-402f-8673-925c82bbd2fb/small/abivax-logo-rgb-png.png https://www.healthcaretribunefrance.com/article/914437171-abivax-pr-sente-ses-r-sultats-financiers-du-t1-2026-et-les-donn-es-trois-ans-de-l-tude-108-un-essai-d-extension-ouvert-de-phase-2a-2b-valuant Healthcare Tribune France en PressRelease 2026-05-22T20:05:00+00:00 Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH https://ml-eu.globenewswire.com/media/5470cd7e-c1fe-402f-8673-925c82bbd2fb/small/